EpiCast Report: Duchenne Muscular Dystrophy - Epidemiology Forecast to 2020 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

EpiCast Report: Duchenne Muscular Dystrophy - Epidemiology Forecast to 2020

Description:

Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Identifying and Commercializing First-in-Class Innovation Detailed report at: – PowerPoint PPT presentation

Number of Views:41

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: EpiCast Report: Duchenne Muscular Dystrophy - Epidemiology Forecast to 2020


1

EpiCast Report Duchenne Muscular Dystrophy -
Epidemiology and Becker Muscular
Dystrophy Forecast to 2020

Published By GBI Research
Published May 2015
2
Description


Highly Innovative and Diverse Pipeline GBI
Research analysis revealed a high degree of
innovation and diversity in this indication, with
70 of the pipeline being first-in-class
products, acting on 13 first-in-class targets.
The Duchenne Muscular Dystrophy (DMD) and Becker
Muscular Dystrophy (BMD) pipeline consists of 84
molecules across all stages of development. Detai
led report at http//www.reportsandintelligence.c
om/frontier-pharma-duchenne-muscular-dystrophy-and
-becker-muscular-dystrophy-identifying-and-commerc
ializing-first-in-class-innovation-market This
exceptional first-in-class innovation is largely
due to the high number of first-in-class products
solely targeting the dystrophin gene, which is
the primary genetic cause of DMD and BMD. The
strong presence of first-in-class products in the
pipeline therefore creates a distinctly different
landscape to the market landscape, which relies
on symptomatic treatment glucocorticoids.
3
Description


Despite a strong focus on personalized treatments
that treat the genetic cause of the disease in
the DMD/BMD pipeline, innovation is also
concentrated on novel molecular targets that
alleviate the dystrophic pathology regardless of
gene mutations, thereby allowing widespread use
in contrast to the mutation-specific
treatments. These therapies are expected to be
used alongside primary treatment to repair the
mutated gene, halt muscle degeneration, and
improve life expectancy of patients in the future
market. Strong Alignment of Innovation to
Genetics and Disease Processes in Early
Pipeline Analysis also indicates opportunities
for some of the first-in-class DMD/BMD targets to
be repositioned to other MDs, although this is
expected to be challenging given the currently
limited understanding of the common molecular
processes defected across multiple types of MD.
4
Description


Numerous Investment Opportunities in Deals
Landscape Strategic consolidation is relatively
uncommon in the DMD/BMD market, with 15 licensing
agreements and 18 co-development deals between
2006 and April 2015. Supported by findings from
the industry-wide analysis, there is a tendency
for first-in-class DMD programs to attract higher
deal values than non-first-in-class programs,
thus highlighting their commercial
attractiveness. With 36 first-in-class products
that are currently in development having not yet
been involved in a licensing or co-development
deal, there are numerous opportunities for
in-licensing or co-development in this
indication. Web link http//www.reportsandintell
igence.com/
5
Table of Contents

  • 1 Table of Contents
  • 1.1 List of Tables
  • 1.2 List of Figures
  • 2 Executive Summary
  • 2.1 Biologics Growing in Prominence in
    Asthma Treatment
  • 3 The Case for Innovation in Asthma
  • 3.1 Growing Number of Opportunities for
    Biologic Products
  • 4 Clinical and Commercial Landscape
  • 4.1 Disease Overview
  • 5 Assessment of Pipeline Product Innovation
  • 5.1 Asthma Pipeline by Phase, Molecule Type
    and Therapeutic Target 

6
Table of Contents

  • 6 Signaling Network, Disease Causation and
    Innovation Alignment 
  • 7 First-in-Class Target and Pipeline Program
    Evaluation
  • 8 Deals and Strategic Consolidations
  • 9 Appendix 62
  • For inquiry, kindly contact at
    http//www.reportsandintelligence.com/enquire-abou
    t-report/245546
  • To check table of contents of the research, Visit
    _at_ http//www.reportsandintelligence.com/frontier-
    pharma-duchenne-muscular-dystrophy-and-becker-musc
    ular-dystrophy-identifying-and-commercializing-fir
    st-in-class-innovation-market/table-of-contents

7

FOR MORE DETAILS
Visit us at
http//www.reportsandintelligence.com/frontier-pha
rma-duchenne-muscular-dystrophy-and-becker-muscula
r-dystrophy-identifying-and-commercializing-first-
in-class-innovation-market
Stay With Us
TELEPHONE Direct 1 (617) 674-4143 Toll Free
1 (855) 711-1555E-MAIL sales_at_reportsandintellig
ence.com
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
About PowerShow.com